cliffwatch

bromocriptine mesylate · Veroscience · NDA 020866

Cycloset

Earliest generic entry, as listed
30 Apr 2032

Blocked by patent: US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 10688094, US 11000522, US 11000522, US 11000522, US 11000522, US 11666567, US 11666567, US 11666567, US 11666567, US 8431155, US 8613947, US 9192576, US 9522117, US 9522117, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9700555, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474, US 9993474.

Listed patents · 126 unexpired

PatentClaimsExpires
US 10688094use U-288230 Apr 2032
US 10688094use U-288430 Apr 2032
US 10688094use U-288730 Apr 2032
US 10688094use U-288530 Apr 2032
US 10688094use U-288130 Apr 2032
US 10688094use U-287630 Apr 2032
US 10688094use U-287430 Apr 2032
US 10688094use U-287330 Apr 2032
US 10688094use U-288030 Apr 2032
US 10688094use U-287730 Apr 2032
US 10688094use U-287030 Apr 2032
US 10688094use U-287530 Apr 2032
US 10688094use U-287830 Apr 2032
US 10688094use U-287230 Apr 2032
US 10688094use U-287130 Apr 2032
US 10688094use U-287930 Apr 2032
US 10688094use U-288630 Apr 2032
US 10688094use U-288830 Apr 2032
US 10688094use U-288330 Apr 2032
US 11000522use U-312230 Apr 2032
US 11000522use U-312030 Apr 2032
US 11000522use U-312130 Apr 2032
US 11000522use U-311930 Apr 2032
US 11666567use U-401830 Apr 2032
US 11666567use U-401730 Apr 2032
US 11666567use U-401630 Apr 2032
US 11666567use U-401530 Apr 2032
US 8431155product, use U-97630 Apr 2032
US 8613947product, use U-97630 Apr 2032
US 9192576product, use U-97630 Apr 2032
US 9522117product, use U-97630 Apr 2032
US 9522117product, use U-193930 Apr 2032
US 9700555product, use U-219230 Apr 2032
US 9700555product, use U-219030 Apr 2032
US 9700555product, use U-219430 Apr 2032
US 9700555product, use U-218830 Apr 2032
US 9700555product, use U-218430 Apr 2032
US 9700555product, use U-219130 Apr 2032
US 9700555product, use U-218730 Apr 2032
US 9700555product, use U-218330 Apr 2032
US 9700555product, use U-219330 Apr 2032
US 9700555product, use U-218930 Apr 2032
US 9700555product, use U-219830 Apr 2032
US 9700555product, use U-218630 Apr 2032
US 9700555product, use U-218530 Apr 2032
US 9700555product, use U-219530 Apr 2032
US 9700555product, use U-219730 Apr 2032
US 9700555product, use U-219630 Apr 2032
US 9993474use U-238930 Apr 2032
US 9993474use U-239330 Apr 2032
US 9993474use U-238530 Apr 2032
US 9993474use U-239130 Apr 2032
US 9993474use U-238730 Apr 2032
US 9993474use U-239230 Apr 2032
US 9993474use U-238630 Apr 2032
US 9993474use U-238830 Apr 2032
US 9993474use U-239030 Apr 2032
US 9993474use U-238430 Apr 2032
US 10688155use U-29217 Jun 2030
US 10688155use U-29327 Jun 2030
US 10688155use U-29247 Jun 2030
US 10688155use U-29267 Jun 2030
US 10688155use U-29317 Jun 2030
US 10688155use U-29277 Jun 2030
US 10688155use U-29187 Jun 2030
US 10688155use U-29337 Jun 2030
US 10688155use U-29167 Jun 2030
US 10688155use U-29207 Jun 2030
US 10688155use U-29227 Jun 2030
US 10688155use U-29197 Jun 2030
US 10688155use U-29307 Jun 2030
US 10688155use U-29177 Jun 2030
US 10688155use U-29257 Jun 2030
US 10688155use U-29297 Jun 2030
US 10688155use U-29237 Jun 2030
US 10688155use U-29377 Jun 2030
US 10688155use U-29287 Jun 2030
US 10688155use U-29347 Jun 2030
US 10688155use U-28987 Jun 2030
US 10688155use U-29057 Jun 2030
US 10688155use U-29027 Jun 2030
US 10688155use U-28907 Jun 2030
US 10688155use U-29147 Jun 2030
US 10688155use U-29117 Jun 2030
US 10688155use U-29037 Jun 2030
US 10688155use U-22817 Jun 2030
US 10688155use U-29017 Jun 2030
US 10688155use U-29127 Jun 2030
US 10688155use U-28917 Jun 2030
US 10688155use U-28967 Jun 2030
US 10688155use U-28937 Jun 2030
US 10688155use U-28997 Jun 2030
US 10688155use U-29047 Jun 2030
US 10688155use U-29007 Jun 2030
US 10688155use U-29067 Jun 2030
US 10688155use U-29087 Jun 2030
US 10688155use U-29137 Jun 2030
US 10688155use U-28947 Jun 2030
US 10688155use U-29107 Jun 2030
US 10688155use U-28927 Jun 2030
US 10688155use U-28957 Jun 2030
US 10688155use U-29097 Jun 2030
US 10688155use U-28977 Jun 2030
US 10688155use U-29077 Jun 2030
US 10688155use U-29367 Jun 2030
US 10688155use U-29157 Jun 2030
US 10688155use U-29357 Jun 2030
US 8877708product, use U-17067 Jun 2030
US 9352025use U-21177 Jun 2030
US 9352025use U-21127 Jun 2030
US 9352025use U-21137 Jun 2030
US 9352025use U-21117 Jun 2030
US 9352025use U-21167 Jun 2030
US 9352025use U-21147 Jun 2030
US 9352025use U-21157 Jun 2030
US 9352025use U-21197 Jun 2030
US 9352025use U-21187 Jun 2030
US 9895422use U-22857 Jun 2030
US 9895422use U-22867 Jun 2030
US 9895422use U-22847 Jun 2030
US 9895422use U-21147 Jun 2030
US 9895422use U-21167 Jun 2030
US 9895422use U-22877 Jun 2030
US 9895422use U-22817 Jun 2030
US 9895422use U-22837 Jun 2030
US 9895422use U-22827 Jun 2030

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
020866 · 001 · RLDtablet, oralEQ 0.8MG BASE30 Apr 2032